{"filings":[{"id":748476,"accession_number":"0001628280-26-039233","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-05-29T20:54:45+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter Amendment increases authorized common shares from 100M to 300M, filed with Nevada on May 28, 2026.","Approved at May 26 annual meeting: 20,594,286 for, 2,875,605 against, 59,533 abstain.","All six director nominees elected including CEO Punit Dhillon, each >13M votes for.","CBIZ CPAs P.C. ratified as independent auditor for FY 2026: 22,802,045 for, 542,634 against.","Advisory 'say-on-pay' approved: 12,696,055 for, 909,925 against, with 9,823,126 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470236,"accession_number":"0001628280-26-035535","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-05-15T20:00:10+00:00","items":["3.01"],"status":"ready","headline":"Skye Bioscience receives Nasdaq delisting notice for failing minimum stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $9,011,804, below Nasdaq Global Market's $10M minimum requirement.","Nasdaq gave 45 days (until June 29, 2026) to submit a compliance plan; extension possible to Nov 9, 2026.","No immediate impact on trading; stock continues to trade under 'SKYE'.","Company is evaluating alternative courses of action to regain compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93331,"accession_number":"0001628280-26-023903","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K/A","filed_at":"2026-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Skye Bioscience amends 8-K to correct option repricing share count to 2,458,158","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment corrects a scrivener's error: total shares underlying Repriced Options is 2,458,158.","No other changes to the original April 3, 2026 8-K filing on compensatory arrangements.","CEO Punit Dhillon signed the amendment dated April 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93332,"accession_number":"0001628280-26-023699","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.","Board approved repricing of 2,420,978 outstanding options held by full-time employees to $0.6150/share (closing price on repricing date).","Repriced options previously had exercise prices ranging from $1.055 to $14.56; include 1,103,959 options held by CEO Punit Dhillon and 396,295 held by COO Tuan Diep.","Option repricing intended to retain and motivate eligible participants without additional dilution or cash compensation.","Master Services Agreement with Lohman & Associates entered; Sharp will serve as principal financial and accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104878,"accession_number":"0001628280-26-019878","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Skye Bioscience receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency letter on March 17, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.","Has 180 calendar days (until Sept 14, 2026) to regain compliance; stock continues trading on Nasdaq Global Market.","May qualify for second 180-day compliance period on Nasdaq Capital Market if meets other listing requirements.","Company considering options including reverse stock split; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104877,"accession_number":"0001628280-26-016400","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.","Interim 52-week data: nimacimab+semaglutide achieved 22.3% mean weight loss; no plateau observed.","Initiated CBeyond Expansion Study: higher doses (400 mg and 600 mg IV) vs placebo; topline Q4 2026.","Weight regain during 13-week off-treatment: combo cohort regained 17.8% vs 37.3% for semaglutide alone.","FDA Type C meeting completed; feedback informing Phase 2b design including potential add-on with incretin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104876,"accession_number":"0001628280-26-010186","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Kaitlyn Arsenault to step down Feb 20; CEO Punit Dhillon appointed principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Kaitlyn Arsenault departs Feb 20, 2026; no disagreement with auditors or company on financials.","Severance: $450,000 cash, $45,000 annual bonus, up to $30,000 legal fees, $41,172 COBRA reimbursement.","Arsenault will serve as advisor for 6 months; outstanding equity awards continue vesting.","CEO Punit Dhillon appointed principal accounting officer effective Feb 20; remains CEO and President."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104875,"accession_number":"0001628280-26-004451","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Skye Bioscience reports 52-week weight loss of 22.3% for nimacimab+semaglutide combo; no plateau observed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.","Weight regain at 13-week off-therapy follow-up was 17.8% for combo vs 37.3% for semaglutide alone, a >50% reduction in rebound.","No serious adverse events or AESIs reported during 52-week extension; safety profile maintained.","Full topline Phase 2a extension data expected in Q3 2026; cash runway into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121135,"accession_number":"0001628280-25-058729","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.","Halozyme to be exclusive supplier of clinical and commercial rHuPH20 API for the product.","Milestone payments tied to development, commercialization, and net sales levels; mid-single digit royalties on worldwide net sales.","Agreement includes customary termination rights, reps, warranties, and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121134,"accession_number":"0001628280-25-051035","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Skye Bioscience Q3: Nimacimab + semaglutide shows 29% greater weight loss vs semaglutide alone; net loss $12.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.","Combination reduced waist circumference by 3.2 cm (1.25 inches) vs semaglutide alone.","Rebound weight gain was 18.1% vs 49.8% for semaglutide alone over 12 weeks post-treatment.","Q3 2025 net loss of $12.8M; cash $35.3M; runway into 2027.","Extension study fully enrolled (43 patients); data expected Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121133,"accession_number":"0001628280-25-044223","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Skye Bioscience Reports Phase 2a Data: Nimacimab Monotherapy Misses Endpoint, Combination Shows Added Weight Loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nimacimab monotherapy at 200 mg failed primary endpoint with placebo-subtracted weight loss of -1.26% (p=0.2699, mITT).","Combination of nimacimab + semaglutide achieved -13.2% weight loss vs -10.25% for semaglutide alone (-2.95%, p=0.0372, mITT).","In per protocol analysis, 100% of combination arm achieved >5% weight loss and 67% achieved >10% weight loss.","No increase in gastrointestinal or neuropsychiatric adverse events with nimacimab, and clean safety profile reported.","Preliminary PK showed lower than expected exposure, supporting evaluation of higher dosing in future trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137778,"accession_number":"0001516551-25-000050","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.","Cash, equivalents & short-term investments $48.6M as of June 30, 2025; expected to fund operations through at least Q1 2027.","Phase 2a CBeyond study of nimacimab top-line data expected late Q3/early Q4 2025; extension study enrolling.","Preclinical data: nimacimab + low-dose tirzepatide boosted weight loss beyond optimal tirzepatide; nimacimab reduced post-treatment weight rebound."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155164,"accession_number":"0001516551-25-000046","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["4.01","5.07","9.01"],"status":"ready","headline":"Skye Bioscience changes auditor to CBIZ CPAs; shareholders re-elect board at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor June 9, 2025 after acquisition by CBIZ; CBIZ CPAs engaged for FY 2025.","No disagreements or reportable events during fiscal years 2023-2024 and through June 9, 2025.","At June 6 annual meeting, all 6 director nominees elected; say-on-pay approved (17.1M for, 2.7M against).","Advisory frequency vote set to 1 year; board adopts annual say-on-pay vote policy until 2031.","Ratification of Marcum as auditor passed with 25.4M shares for (99.8% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155163,"accession_number":"0001516551-25-000043","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Skye Bioscience Q1 net loss $11.1M; nimacimab combo shows >30% weight loss in preclinical","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2025 was $11.1M ($2.2M non-cash share-based comp) vs $5.0M in Q1 2024.","Cash and short-term investments total $59.2M; expected to fund operations through at least Q1 2027.","Preclinical DIO model: nimacimab + tirzepatide achieved >30% weight loss; nimacimab alone 23.5% comparable to monlunabant and tirzepatide alone.","In vitro data shows superior potency of peripherally restricted nimacimab vs small molecule monlunabant under pathological CB1 agonist levels.","Top-line data from Phase 2a CBeyond study of nimacimab expected late Q3/early Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173676,"accession_number":"0001516551-25-000028","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.","Phase 2a CBeyond trial enrolled 136 patients; interim analysis removed; data expected late Q3/early Q4 2025.","Net loss FY2024 $26.6M vs $37.6M in 2023 (prior year included $21.2M IPR&D charge).","R&D expense FY2024 $18.7M (up from $5.8M) driven by Phase 2 trial and manufacturing costs.","Settled insurance litigation, received $2.0M cash proceeds in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173675,"accession_number":"0001516551-25-000002","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Skye Bioscience board approves amended inducement equity plan with broader change-in-control authority","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment gives administrator broader authority to cancel, assume, accelerate, or cash out outstanding awards upon a Change in Control.","Total shares authorized under the plan remain 600,000; no change to share pool.","Plan is used for inducement grants to new employees; all awards must be approved by a majority of independent directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190638,"accession_number":"0001516551-24-000108","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.","Cash and equivalents $76.5M including restricted $9.1M; court order allows release of $9M restriction before year-end.","Phase 2 obesity trial for nimacimab enrolling; interim data Q2 2025, topline data Q4 2025.","Preclinical DIO mouse model: nimacimab achieved up to 16% weight loss vs vehicle, with fat loss and lean mass preservation.","Appointed Dr. Puneet Arora as Chief Medical Officer and Paul Grayson as Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190637,"accession_number":"0001516551-24-000093","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Skye Bioscience appoints Paul Grayson as Chairman; CEO Dhillon gets salary hike and stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Grayson appointed Chairman effective Oct 25, 2024; CEO Punit Dhillon resigns as Chairman, remains on Board.","CEO Dhillon's base salary increased to $610,000; CFO Arsenault's to $450,000, effective Jan 1, 2025.","Stock options granted: Dhillon 650,000 shares, Arsenault 125,000 shares; 10-year term, 48-month vesting.","Grayson is independent director; currently CEO of Radionetics Oncology, former CEO of Tentarix and founder at Fate Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190636,"accession_number":"0001516551-24-000091","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Skye Bioscience stockholders approve amended omnibus incentive plan, increasing share pool by 1.54M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 17.4M for, 6.2M against to approve the Amended and Restated Omnibus Incentive Plan.","Plan increases authorized shares by 1,535,655 and raises incentive stock option limit to 4,000,000.","Plan expiration extended to September 10, 2034; automatic share replenishment feature retained.","Approval became effective upon stockholder vote at Special Meeting on October 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207133,"accession_number":"0001516551-24-000085","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Skye Bioscience appoints Puneet Arora as Chief Medical Officer, grants 225,000 stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Puneet S. Arora, MD, appointed CMO effective Sept 3, 2024; base salary $475k with 40% target bonus.","Received inducement stock option for 225k shares vesting over 4 years (25% at 1-year, then monthly).","Previously CMO at Lassen Therapeutics, Head of Clinical Dev at Principia (Sanofi), Senior Medical Director at Genentech.","Company focuses on Phase 2 CBeyond obesity trial for nimacimab, a CB1 inhibitor.","Also granted 13,500 share non-qualified option to a new non-executive employee under inducement plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207132,"accession_number":"0001516551-24-000064","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.","Drs. Keith Ward and Praveen Tyle resign from board effective Aug 1, 2024; no disagreement with company.","Grants new General Counsel Brennen Brodersen inducement award: option for 60,000 shares and 15,000 RSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224483,"accession_number":"0001516551-24-000059","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Skye Bioscience Phase 2a trial of SBI-100 OE fails primary endpoint; discontinues ophthalmology program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.","Drug safe; all patients completed study with no early discontinuations due to adverse events.","Company discontinues all SBI-100 development and ophthalmology pipeline; focuses on obesity program with Nimacimab.","Phase 2 obesity trial of Nimacimab expected to start Q3 2024; cash runway extended into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224482,"accession_number":"0001516551-24-000052","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Skye Bioscience reports pro forma equity >$5M after $90M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).","Sold real estate held by subsidiary Avalite Sciences, recording $1.14M gain in pro forma.","Pro forma stockholders' equity rises to $82.5M from ($2.1M) deficit at Dec 31, 2023.","Company believes it now meets Nasdaq's $5M minimum equity requirement for initial listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243793,"accession_number":"0001516551-24-000045","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Skye Bioscience raises $40M via PIPE of 4M shares at $10 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 4,000,000 shares at $10.00 per share for gross proceeds of $40,000,000.","Piper Sandler led placement; Oppenheimer & Co. co-placement agent.","PIPE closed March 13, 2024; warrants amendment adds cashless exercise through Sept 2025.","Directors/officers entered 90-day lock-up agreements; registration rights file within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243792,"accession_number":"0001516551-24-000034","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.","Dr. Jenkins receives annual cash retainer of $40,000 plus committee retainers; option for 40,000 shares vesting over 1 year.","Director Margaret Dalesandro to resign effective Aug 1, 2024, citing no disagreement with company.","Dr. Jenkins brings 25+ years pharma/biotech experience including roles at Merck Serono, BMS, and as CEO of Dimension Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243791,"accession_number":"0001516551-24-000008","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.","Subsidiary Avalite Sciences sold real estate on Jan 19, 2024, contributing ~$1.14M gain to equity.","Pro forma stockholders' equity as of Sept 30, 2023 adjusted to $49.05M from $1.70M.","Company believes equity now exceeds $5M minimum required for initial listing on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243790,"accession_number":"0001516551-24-000002","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.","Co-led by 5AM Ventures and another life science investor; includes Ally Bridge, Sphera, Altium, Driehaus.","Net proceeds expected to fund operations into early 2026, including nimacimab Phase 2 obesity trial starting mid-2024.","Phase 2a SBI-100 OE trial for glaucoma currently enrolling; interim data expected Q1 2024, topline Q2 2024.","Directors and officers subject to 90-day lock-up; registration rights agreement filed within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261194,"accession_number":"0001516551-23-000103","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"Skye licenses SBI-100 to Tautomer for Africa, terminates UM 8930 license, sells Canadian lab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Tautomer for SBI-100 (THC prodrug) suppository in Africa for chronic pain and other indications.","Tautomer to buy $500K of Skye stock within 60 days; potential milestones up to $10.75M plus double-digit royalties.","Terminated UM 8930 license (SBI-200) effective Jan 30, 2024; no milestones met beyond initial $200K payment.","Sold Avalite lab facility in Canada for CAD $1.499M; closing expected Jan 15, 2024.","Skye retains exclusive, perpetual license for UM 5050; deal subject to South African exchange control approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261193,"accession_number":"0001516551-23-000083","cik":1516551,"company_name":"Skye Bioscience, Inc.","ticker":"SKYE","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Skye Bioscience increases authorized common shares from 20M to 100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment on Nov 6, 2023, raising authorized common shares from 20,000,000 to 100,000,000.","No change to issued and outstanding shares; only affects potential future issuances.","Board unanimously approved; majority stockholders consented in writing in lieu of a special meeting.","Amendment provides additional flexibility for future capital raising or strategic transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":29735102.492818344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}